Details

Autor(en) / Beteiligte

• Coughlin, Janelle W
• Nauman, Elizabeth
• Wellman, Robert
• Coley, R Yates
• McTigue, Kathleen M
• Coleman, Karen J
• Jones, Daniel B
• Lewis, Kristina H
• Tobin, Jonathan N
• Wee, Christina C
• Fitzpatrick, Stephanie L
• Desai, Jay R
• Murali, Sameer
• Morrow, Ellen H
• Rogers, Ann M
• Wood, G Craig
• Schlundt, David G
• Apovian, Caroline M
• Duke, Meredith C
• McClay, James C
• Soans, Rohit
• Nemr, Rabih
• Williams, Neely
• Courcoulas, Anita
• Holmes, John H
• Anau, Jane
• Toh, Sengwee
• Sturtevant, Jessica L
• Horgan, Casie E
• Cook, Andrea J
• Arterburn, David E

Titel

Preoperative Depression Status and 5 Year Metabolic and Bariatric Surgery Outcomes in the PCORnet Bariatric Study Cohort

Ist Teil von

• Annals of surgery, 2023-04, Vol.277 (4), p.637-646

Ort / Verlag

United States

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• To examine whether depression status before metabolic and bariatric surgery (MBS) influenced 5-year weight loss, diabetes, and safety/utilization outcomes in the PCORnet Bariatric Study. Research on the impact of depression on MBS outcomes is inconsistent with few large, long-term studies. Data were extracted from 23 health systems on 36,871 patients who underwent sleeve gastrectomy (SG; n=16,158) or gastric bypass (RYGB; n=20,713) from 2005-2015. Patients with and without a depression diagnosis in the year before MBS were evaluated for % total weight loss (%TWL), diabetes outcomes, and postsurgical safety/utilization (reoperations, revisions, endoscopy, hospitalizations, mortality) at 1, 3, and 5 years after MBS. 27.1% of SG and 33.0% of RYGB patients had preoperative depression, and they had more medical and psychiatric comorbidities than those without depression. At 5 years of follow-up, those with depression, versus those without depression, had slightly less %TWL after RYGB, but not after SG (between group difference = 0.42%TWL, P = 0.04). However, patients with depression had slightly larger HbA1c improvements after RYGB but not after SG (between group difference = - 0.19, P = 0.04). Baseline depression did not moderate diabetes remission or relapse, reoperations, revision, or mortality across operations; however, baseline depression did moderate the risk of endoscopy and repeat hospitalization across RYGB versus SG. Patients with depression undergoing RYGB and SG had similar weight loss, diabetes, and safety/utilization outcomes to those without depression. The effects of depression were clinically small compared to the choice of operation.